Medication info
Linaen Duo Extended Release Tablet 2.5/1000 mg (Linagliptin, Metformin)

Linaen Duo Extended Release Tablet 2.5/1000 mg (Linagliptin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›1000mg / 1 tabletLinagliptin Micronized›2.5mg / 1 tablet
Manufacturer / importer
HK inno.N Co., Ltd.
Appearance
Yellow, double convex, oval-shaped extended-release film-coated tablet
Packaging
30 tablets / bottle
Approval status
Active

MFDS item code 202400570 · Approved 2024.03.18 · Insurance code 640007980

Summary

Main use
Improvement of blood glucose control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride (extended-release) 2000 mg. Take this medicine once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. Take one 5/1000 mg extended-release tablet once daily. Patients taking the 2.5/1000 mg extended-release tablet should take two tablets at the same time once daily. 1. Patients not currently receiving metformin: The initial total daily dose of this medicine is linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with metformin plus a sulfonylurea or metformin plus insulin, the initial dose of this medicine should be considered as a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose. - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this medicine, the dose of this medicine is the patient's current dose of linagliptin and extended-release metformin hydrochloride. No dosage adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), with creatinine clearance (CrCl) ≥ 45mL/min and < 60mL/min or estimated glomerular filtration rate (eGFR) ≥ 45mL/min/1.73m2 and < 60mL/min/1.73m2, this medicine may be used with metformin hydrochloride dose adjustment as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to < 45mL/min or estimated glomerular filtration rate (eGFR) decreases to < 45mL/min/1.73m2, discontinue this medicine immediately.

Ingredients

Manufacturer
HK inno.N Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in type 2 diabetes mellitus

View approved original text

This medication is a treatment that helps control blood sugar in patients with type 2 diabetes by using Linagliptin and Metformin together. Taking it along with diet control and exercise therapy can effectively manage blood sugar levels. This leads to stable improvement in blood sugar levels and helps prevent complications of diabetes. It is an actively recommended treatment method for maintaining healthy blood sugar management.

How to take

Adult dose

For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride (extended-release) 2000 mg. Take this medicine once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. Take one 5/1000 mg extended-release tablet once daily. Patients taking the 2.5/1000 mg extended-release tablet should take two tablets at the same time once daily. 1. Patients not currently receiving metformin: The initial total daily dose of this medicine is linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with metformin plus a sulfonylurea or metformin plus insulin, the initial dose of this medicine should be considered as a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose. - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this medicine, the dose of this medicine is the patient's current dose of linagliptin and extended-release metformin hydrochloride. No dosage adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), with creatinine clearance (CrCl) ≥ 45mL/min and < 60mL/min or estimated glomerular filtration rate (eGFR) ≥ 45mL/min/1.73m2 and < 60mL/min/1.73m2, this medicine may be used with metformin hydrochloride dose adjustment as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to < 45mL/min or estimated glomerular filtration rate (eGFR) decreases to < 45mL/min/1.73m2, discontinue this medicine immediately.

Precautions

This medication may cause severe lactic acidosis and hypoglycemia, so caution is required. It should not be used by patients with allergy to the ingredients of this medication, type 1 diabetes, lactic acidosis, or diabetic ketoacidosis. It is also not to be administered to patients with severely impaired renal function or acute diseases that may affect renal function, such as dehydration, severe infections, or acute myocardial infarction. Patients with impaired liver function, acute alcohol intoxication, alcoholism, or malnutrition should also not take this medication. As this medication poses a risk of hypoglycemia, careful dosage adjustment is necessary when used with insulin or sulfonylureas. Regular checks of renal function are required, and if renal function declines, the medication should be discontinued or used cautiously. Skin conditions such as acute pancreatitis or similar bullous diseases may occur; symptoms should immediately be reported to a doctor. This medication may lower vitamin B12 levels, so it is recommended to monitor vitamin B12 levels during long-term use. When taking the tablet, do not crush or chew it; swallow it whole, even if the tablet's coating is excreted. There may be interactions with other medications, so caution is needed, especially when taking medications that affect renal function. It is advisable to avoid use during pregnancy or lactation and to consult a doctor if planning for pregnancy. Elderly patients often have reduced renal function, so dosages should be adjusted and renal function should be monitored regularly. In case of overdose, there is a risk of lactic acidosis, so immediate medical treatment should be sought, and dialysis may be necessary. When storing, keep in a sealed container out of children's reach and avoid moisture, and it is advisable not to transfer to other containers.

Side effects

Severe lactic acidosis, hypoglycemia, angioedema, urticaria, lactic acidosis, abnormal vitamin B12 absorption test results, hypoglycemic episodes, taste disturbance, cough, loss of appetite, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, oral ulcer, abnormal liver function tests, hepatitis, pruritus, erythema, rash, similar to pemphigus, severe and disability-associated arthralgia, rhabdomyolysis, increased lipase, increased amylase, nasopharyngitis, hypersensitivity reaction, constipation, upper abdominal pain, enterocolitis, bowel obstruction, gastroenteritis, herpes zoster, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, decreased appetite, dehydration, hyperglycemia, cerebral infarction, stuttering, Alzheimer's type dementia, chest pain, fever, facial swelling, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot disease, skin lesions, liver metastasis, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pericardial effusion, gastric cancer, rectal cancer, pancreatic cancer, meniscus injury, pneumoconiosis, congestive heart failure, angina pectoris, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage renal disease, acute cholangitis, acute cholecystitis, cholangitis, dizziness, kidney transplant failure, anxiety, affective disorder, insomnia, depression, contusion, bone contusion, concussion, bone fracture, hand fracture, palpitations, dry eye, glaucoma, cataract, ocular discomfort, allergic conjunctivitis, polyuria, proteinuria, stress urinary incontinence, hematuria, hypotension, flushing, hepatic steatosis, cholelithiasis, hearing loss, erectile dysfunction, goiter, anemia, nausea, gastroesophageal reflux disease, gastritis, dizziness, sensory decrease, chest discomfort, weakness, pain, nosebleed, oropharyngeal pain, voice disorder, epistaxis, runny nose, pulmonary mass, arthralgia, osteoporosis, arthropathy, musculoskeletal discomfort, myositis, myalgia, soft tissue mass, postmenopausal osteoporosis, rotator cuff syndrome, increased triglycerides in blood, increased urine albumin/creatinine ratio, positive urine leukocytes, decreased hemoglobin, increased serum potassium, increased serum creatinine, increased serum creatine phosphokinase activity, increased ALT, androgenic alopecia, hyperhidrosis, dermatitis, anxiety, altered mental status, nocturia, dermatitis, hypertension

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly sealed container to prevent exposure to air and moisture. It should be kept at room temperature, specifically between 1°C and 30°C, to maintain its effectiveness.

Appearance and packaging

Appearance

Yellow, double convex, oval-shaped extended-release film-coated tablet

Package unit

30 tablets / bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.